Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the first results from the open-label extension trial of the Phase 3 GATHER2 study, which demonstrated ...

The EURETINA meeting attracted over 11,000 attendees, showcasing advancements in retinal disease treatments, including gene ...

Early treatment with Izervay demonstrated increased efficacy in slowing geographic atrophy lesion growth over time, according ...

Please provide your email address to receive an email when new articles are posted on . Science Corporation reported positive preliminary results of a clinical trial examining its Prima retinal ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye, and it marks the first of a three-part series on dry ...

Distinct retinal vessel atrophy patterns may be associated with multiple sclerosis (MS), but further research is needed to assess retinal vessel changes and their underlying role in MS. Changes in the ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

A real-world analysis has confirmed the negative impact on patients when they lose copay assistance for treatments for retina and macular disease. Presented today during a session at the annual ...

Progressive retinal atrophy in dogs is a genetic condition that affects a dog’s vision. Unfortunately, it can cause a dog to lose their vision. Unfortunately, certain breeds suffer from the condition ...

A research team from the Medical University of Vienna and the Medical University of Graz has discovered a previously unknown ...

CHICAGO--(BUSINESS WIRE)--University Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical ...